About Abbott Laboratories (ABT)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and

ABT Key Statistics

ABT Price Performance

Abbott Laboratories stock has returned -1.82% over the past day, -4.49% over the past week, -0.39% over the past month, and -10.67% over the past three months. The stock trades between a 52-week low of $105.27 and a high of $139.15.

ABT Financial Fundamentals

Abbott Laboratories reports a return on equity (ROE) of +13.03%, operating margin of +18.71%, profit margin of +1466.34%, and revenue growth of +4.40%. The debt-to-equity ratio is 0.27. Current ratio stands at 1.58.

ABT Earnings

Abbott Laboratories's next earnings report is expected on 2026-04-15 (41 days away). The company has a +0.25% earnings beat rate with an average surprise of -0.42%. Earnings consistency is rated as "low".

ABT Ownership

Institutional investors hold approximately +0.82% of ABT shares across 10 institutions. Insider ownership is +0.01%. Insider sentiment is "bearish".

ABT Short Interest

ABT has a short interest of +0.99% of float with a short ratio (days to cover) of 1.3.

ABT AI Analysis Signal

iGotFomo's AI-powered signal engine rates ABT as "BUY" with MEDIUM confidence (score: 39/100). 8 signals are bullish, 2 are bearish, and 3 are neutral.